Intravenous injection of peptide nanovaccines could enhance the population of stem‐like TCF1+CD8+ T cells to improve their antitumor immunity compared with s.c. immunization.[45] In the present study, we propose an optimized approach to efficiently stimulate the tumor‐spleen immunity cycle to inhibit established mouse tumor models, which also involves i.v. injection of C‐N‐LNPs‐vaxD18. The gene discussed is CD8A; the disease is neoplasm.